Health Care & Life Sciences » Pharmaceuticals | Pharmally International Holding Co. Ltd.

Pharmally International Holding Co. Ltd. | Cash Flow

Fiscal year is January-December. All values TWD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
816
1,043
1,214
1,088
1,116
1,361
Depreciation, Depletion & Amortization
119
121
115
120
150
183
Other Funds
195
280
315
113
156
310
Funds from Operations
740
885
1,013
1,094
1,110
1,234
Changes in Working Capital
91
120
15
61
88
17
Net Operating Cash Flow
650
765
998
1,155
1,022
1,251
Capital Expenditures
152
23
629
876
703
Sale of Fixed Assets & Businesses
-
-
-
240
59
Purchase/Sale of Investments
1
-
1,055
640
517
Net Investing Cash Flow
151
23
1,683
1,276
1,161
Cash Dividends Paid - Total
146
-
520
598
520
Issuance/Reduction of Debt, Net
125
111
-
1,537
603
Net Financing Cash Flow
272
111
1,351
939
42
Net Change in Cash
270
685
603
726
174
Free Cash Flow
498
742
369
573
321
Change in Capital Stock
-
-
1,871
-
1,165
Exchange Rate Effect
43
54
62
92
77
Other Uses
-
-
-
-
-

About Pharmally International Holding Co.

View Profile
Address
18th Floor
Taipei TP 11012
Taiwan
Employees -
Website http://www.pharmally.com
Updated 07/08/2019
Pharmally International Holding Co., Ltd. engages in the manufacture and sale of infusion and active pharmaceutical ingredient (API) products. It focuses on basic infusion, infusion therapy, and API. Its products include glucose, sodium chloride, glucose & sodium chloride, compound sodium chloride, lactated ringer's, dextran 40 glucose, dextran 20 glucose, ambroxol hydrochloride & glucose, levofloxacin lactate & sodium chloride injections, nikethamide, dextran powder, and levofloxacin lactate powder.